|
|
|
- Fewer infections: 69% reduced infection rate compared with catheters1
- Superior Dialysis Adequacy: 1.7Kt/V, a 16% to 32% improvement compared with catheters1
- High Patency Rates: Up to 87% cumulative patency at 2 years1,2
- Cost Savings: A 23% average savings per year compared with catheters3
A full bibliography is available on the Publications page.
1Katzman, MD, et al., J Vasc Surg 2009. 2Gage et al., EJVES 2012. 3Dageforde et al., JSR 2012. 4IFU: Comparisons to catheters and AVGs are from literature review on file. 5 Dhingra et al., Kidney Int 2001. 6 2006 NKF KDOQI, Guideline 4.
ML0460.000
|
INDICATIONS FOR USE: The HeRO Graft is indicated for end stage renal disease patients on hemodialysis who have exhausted all other access options. Rx Only. See instructions for use for full indication, contraindication and caution statements. Terms and Conditions. Privacy Policy. HeRO is a Hemosphere, Inc. product distributed by CryoLife, Inc. HeRO, Hemosphere, CryoLife, ‘Life Restoring Technologies’, and the snowflake symbol are trademarks owned by CryoLife, Inc. or its subsidiaries. All other trademarks are owned by their respective companies. © 2012 CryoLife, Inc. All Rights Reserved.